Objective To study the expression of the imprinted gene H19 and IGF-Ⅱ in newborn placenta,and to discuss its influence on the birth body mass of the neonate. Methods The fresh placental tissues from full-term newborn (without trimester of pregnancy complica-tion and placenta and funic abnormality) with normal,high and low birth body mass (12,10 and 8 samples respectively)were collected. The expression of imprinted gene H19 and IGF-Ⅱ mRNA in the placenta were estimated by reakime fluorescence quantitative PCR Results The ex-pression of H19 mRNA in the placenta was negative correlation to the birth body mass (r =-0.403,P = 0.027).The expression of of IGF-H mRNA was positive correlated to the birth body mass (r = 0.444,P = 0.014). The H19 mRNA expression level in the high birth weight neonates (0.21 0.31) was significantly lower than that in the low birth body mass neonates (1.51 2.04)(P= 0.013). But the expression level of IGF-Ⅱ mRNA in the high birth body mass neonates (2.67±3.41) was significantly higher than that in the low birth body mass neonates (0.39±0.33)(P =0.013). Conclusion The expression of H19 and IGF-Ⅱ mRNA was significantly different in the placenta of normal,high and low birth body mass newboms. These two genes may be related to the birth body mass,and there may be some realation-ship between these two genes.

Objective To study the protective effect of the hypothermic brain-protection apparatus on hemorrhagic shock rabbits. Methods Applying the modified Wigger's shock animal model, we observed the effects of a self-developed brain-protecting apparatus on the survival time and vital signs of rabbits. Results Hypothermic brain protection could considerably reduce 60% lipid hyperoxide in brain tissues as compared with that in the control group. It could also decrease heart rate and respiration and hence reduce tissue oxygen consumption. Conclusion Hypothermic brain protection can attenuate the brain lesion and obviously prolong the survival time of hemorrhagic shock animals.

Objective To evaluate the efficacy and safety of specific immunotherapy (SIT) to allergic rhinitis in children.Methods Sixty-four patients with mite allergy allergic rhinitis in children,were divided into two groups by random digits table:treatment group and control group,each group with 32 cases.Treatment group was given SIT with standardized allergen vaccine for 3 years on the basis of symptomatic therapy,control group only received symptomatic therapy.Observation indexs included rhinitis symptoms score,drug score,skin index (SI),serum specificity IgE (sIgE),peripheral eosinophil (Eos) counting,development of asthma and the new sensitization.Results The Eos counting,SI after treatment 3 years in treatment group were significantly better than those before treatment and those in control group after treatment 3 years[(0.14 ± 0.12) × 109/L vs.(0.74 ± 0.18) × 109/L,(0.78 ± 0.36) × 109/L and 1.03 ± 0.13 vs.1.51 ± 0.32,1.51 ± 0.37] (P ＜ 0.01).There was no statistically significant difference in sIgE between two groups (P ＞0.05).The rhinitis symptoms score,drug score in two groups after treatment 1,2,3 years were significantly better than those before treatment (P ＜ 0.01).The rhinitis symptoms score,drug score in treatment group after treatment 1,2,3 years were significantly better than those in control group(P ＜ 0.01).The rate of new sensitization in treatment group was significantly lower than that in control group [3.1％ (1/32)vs.34.4％ (11/32),P ＜ 0.01].Conclusion Keeping long-term SIT is effective and safe for children's allergic rhinitis induced by mite,it also prevents new allergen appeared and allergic rhinitis development for asthma.

Objective We compared the difference of diagnosing macrosomia using the body mass index (BMI)and body mass,so as to investigate whether BMI play an important role in the diagnosis and management of macrosomia in our clinical work.Methods We analysed 5522 newborns (without any maternal complication)delivered in Shengjing Hospital of China Medical University from Jan.2004 to Apr.2009,all of them were full term,singleton and with the birth body mass larger than 2500 g,among them 4989 were in the group with body mass <4000 g,that was 2510-4000 g.533 cases were in the group of body mass ≥4000 g.By both body mass and length,we got the BMI.According to statistical receiver operating characteristic curve(ROC),we determined the cutoff of BMI for diagnosing macrosomia,in addition the sensitivity and specificity of it. Using this newly gotten BMI cutoff as a method to diagnose macrosomia and analyse the results.Results (1)When the newborns with birth length 40-43 cm.the mean birth body mass was(3010 ±351)g,BMI was(17.0 ±2.7)kg/m2;the newborns with birth length 48-51 cm,the mean birth body mass was(3450 ±313)g,BMI was(13.2±1.4)kg/m2;newborns with birth length 56-60 cm,the mean birth body mass was(4332 ±456)g,BMI was(12.5 ±1.3)kg/m2,The longer the birth length,the larger the birth body mass,while the less BMI.(2)Determined by ROC curve,the BMI value could be used to diagnose macrosomia was 14.2 kg/m2.with sensitivity of 78.4% and specificity of 85.0%, the area of under curve was 0. 892. (3) By the BMI cutoff ( 14. 2 kg/m2 ), 111 macorsomia with birth body mass ≥4000 g were not macrosomia any more (20. 8%, 111/533 ),422 still were macrosomia (79.2% ,422/533) ; while for those birth body mass <4000 g, 728 were macrosomia determined by this BMI cutoff ( 14. 59%, 728/4989 ), 4261 were still not macrosomia ( 85.41%, 4261/4989 ). Using BMI cutoff 14. 2 kg/m2 to diagnose macrosomia, within the group of birth body mass ≥4000 g, their birth length in macrosomia and non macrosomia was (52. 2 ± 1.8) cm and ( 55.6 ± 1.3 ) cm respectively, the difference was significant (P <0. 01 ) ;while within the group with body mass <4000 g, the birth length of macrosomia and non-macrosomia was (49.0 ±2. 2) cm and (50. 8 ±2. 2) cm respectively,the difference was significant as well (P <0. 01 ). The whole incidence of macrosomia was 20. 83% (1150/5522) determined by this BMI cutoff. Conclusions Birth body mass and BMI in determining macrosomia show some bias, and birth length relates with this difference, which suggests birth length maybe play an important role in determine the macrosomia. We suggest it is very necessary to use BMI≥ 14. 2 kg/m2 in the diagnosis and management of macrosomia.

OBJECTIVE: To evaluate the efficacy of mite allergen specific immunotherapy (SIT) to patients of allergic rhinitis. METHOD: A total of 102 patients with mite allergy were recruited into the study. They were randomly divided into two groups: SIT group (n = 51) and ST (symptomatic therapy) group (n = 51). They were given SIT with standardized allergen vaccine for 3 years or only symptomatic therapy respectively. Observation items include: rhinitis symptom scores, drug score, skin prick test result, serum specificity IgE (sIgE), peripheral eosinophil counting. The development of asthma and new allergens sensitization was also assessed. RESULT: The blood eosinophil numbers, skin test index, rhinitis symptom scores and drug scores were all decreased significantly after the treatment with SIT for 3 years compared to that of ST group (P < 0.01). Although the level of serum slgE was decreased, no statistic diferences were found. No patients developed asthma in SIT group, and only 2.1% of patients had new allergen sensitization; 17.4% of those in ST group developed asthma, 32.6% had new sensitization. No severe adverse events occurred. CONCLUSION Keeping long-term SIT is effective and safe for patients with allergic rhinitis induced by mite, which can also prevent new allergen sensitization and development for asthma.
Adolescent ; Adult ; Antigens, Dermatophagoides ; administration & dosage ; Child ; Desensitization, Immunologic ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Rhinitis, Allergic ; therapy ; Treatment Outcome ; Young Adult

Objective To analyze the clinical characteristics,therapy and follow-up of the patients with ulcerative colitis (UC).Methods Collect the date of 77 inpatients with UC at the Second Affiliated Hospital of Chongqing Medical University be-tween November,2009 and october,2014,and assigned the patients randomly.Results 69.9% of the patients who were in the ac-tivity stage were moderate severity.E2 (46.6%,34/73)and E3 (50.7%,37/73)were the common lesions range.The main clinical manifestations were abdominal pain,diarrhea,mucopurulent bloody stool and bloody stool.The enteroscopy mostly showed that in-testinal mucosa hyperemia,eddma,erosion,and small ulcers had the common features of UC.The common biopsy results were chro-nic inflammation and/or erosion.The average value of serum ALB decreases while the severity of UC patients increases.Drug thera-py was the main treatment of UC.The maintenance therapy was aminosalicylic acid,the effective ratio of treatment is 89.0%(55/73).Conclusion UC treatment plan basically follow the consensus and we should enhance the follow-up of UC patients.

OBJECTIVE: To evaluate the effect of allergen specific immunotherapy (SIT) in patients with allergic rhinitis and asthma. METHOD A total of 68 patients with allergic rhinitis and asthma sensitized to dust mite were recruited into the study. They were randomly divided into two groups: SIT group n = 34 and symptomatic therapy (ST) group: n = 34. Patients in ST group received medication to treat, the symptoms, patients in SIT group received medication and 3 years of standardized allergen vaccine therapy. Evaluation index of therapy includes: rhinitis symptoms score, asthma symptoms score, drug score, skin prick test, serum specificity IgE (sIgE) , peripheral eosinophil (Eos) counting, lung function. The new sensitinogen rate was also assessed. RESULT: Clinical symptom scores, drug scores, lung function, blood eosinophil numbers and skin test result were all improved significantly after 3-year treatment in SIT group compared to those in ST group (P < 0.01). Although the level of serum slgE was decreased,there exited no statistic diferences between two groups. Only 8.8% patients have the new sensitization in SIT group, and 52.9% in ST group. There were no serious adverse reactions in treatment process. CONCLUSION SIT for patients with AR and asthma can obtain excellent clinical efficacy.
Animals ; Asthma ; drug therapy ; Desensitization, Immunologic ; Eosinophils ; Humans ; Immunoglobulin E ; blood ; Leukocyte Count ; Pyroglyphidae ; Rhinitis, Allergic ; drug therapy ; Sensitivity and Specificity ; Skin Tests

Objective To analyze the clinical pathological characteristics of achalasia patients complicated by esophageal cancer.Methods From January 2005 to May 2013,among 658 patients with achalasia,the clinical data,pathological characteristics of tumor and the treatment of those complicated by esophageal cancer were collected and analyzed.At the same time,receiver operating characteristic (ROC) curve analysis was performed to analyze the relationship between the course of achalasia and esophageal cancer.Results Among the 658 patients with achalasia,297(45.1％) cases were male and 361(54.9％) cases were female.A total of 62 cases (9.4％) were lost to follow-up and of 596 cases who completed the follow-up,26 cases (4.4 ％) were complicated with esophageal cancer.Among the 26 patients complicated with esophageal cancer,69.2％ (18/26) were male;the course from achalasia diagnosed to esophageal cancer was (16.5±8.2) years.The patients with a disease duration more than 10 years accounted for 88.5％(23/26),and 80.8％ (21/26) underwent previous balloon dilatation or Heller surgery.The predilection site of esophageal cancer was in the middle esophagus of patients complicated by esophageal cancer (69.2％,18/26),the main type was squamous carcinoma (88.5％,23/26),65.4％(17/26) of the lesions invaded to muscular layer (stage T3 to T4),61.5％(16/26) had the late stage tumor (stage Ⅲ to Ⅳ),and 23.1％(6/26) had distant metastasis.The results of ROC curve analysis showed that when the duration was 10.5 years,the Youden index reached the maximum value (0.71).And 38.5％ (10/26) of patients with esophageal cancer could not be treated with esophageal cancer radical surgery,and their average survival time was (11.4±6.6) months.Conclusion The patients with the duration of achalasia over 10.5 years are required for regular endoscopic examination to improve the prognosis.

BACKGROUND:Bone marrow mesenchymal stem cells(BMSCs)differentiating into neural cells is an effective way of cell therapy of nervous system disease.However,the methods used nowadays still need to be improved.OBJECTIVE:To induce the differentiation of rhesus monkey BMSCs into neuron-like cells by using sonic hedgehog factor.METHODS:Rhesus monkey BMSCs differentiating into neuron-like cells was induced by typical retinoic acid and sonic hedgehog factor.Rhesus monkey BMSCs were isolated and cultured by density gradient centrifugation method.Cell growth was observed under an inverted phase contrast microscope and cell growth curve was determined using MTT assay.Flow cytometry was performed to characterize the phenotype of BMSCs,and immunohistochemistry was utilized to assess differentiated cells.Ultra-structure of the differentiated cells was observed by transmission and scanning electron microscopes.RESULTS AND CONCLUSION:Rhesus monkey BMSCs cultured in vitro were identified by flow cytometry,with high homogenicity.Following sonic hedgehog factor disposal for 7 days,differentiated cells were mainly positive for neurone specific enolase,neurofilament protein,Tau and glial fibrillary acidic protein(GFAP).Image statistical analysis found that in sonic hedgehog factor scheme,neural stem cells marker Neetin positive rate was significantly higher compared with the rstinoic acid scheme(P＜0.01).GFAP-positive rate was greater in the retinoic acid scheme than in the sonic hedgehog factor scheme(P＜0.05).Results indicated that sonic hedgehog factor scheme is an effective pathway of rhesus monkey BMSC differentiation into neuron-like cells.

BACKGROUND: Present studies have demonstrated that during neural development, differentiation of neural stem cells (NSCs) was affected by various regulatory factors from surrounding microenvironment. Sonic hedgehog (Shh) is a key induction signal during neural fetal development, and can be an effective inductor to regulate differentiation of neural cells. OBJECTIVE: To investigate the signal transduction pathway of SHH for differentiation of rhesus monkey bone marrow mesenchymal stem cells (BMSCs) into of neuron-like cells by sonic hedgehog factor. METHODS: Rhesus monkey BMSCs were isolated and cultured by conventional density gradient centrifugation. BMSCs in the induction group were treated with L-DMEM containing FGF2, B27 and fetal bovine serum for preinduction of 24 hours, and then with DMEM supplemented with 0.5 μmol/L retinoic acid or 400 μmol/L SHH for 8 days. Non-induced cells served as control group. Following labeling with neuron enolase, positive cells were screened by flow cytometry. RT-PCR and Western-blot were used to detect SHH- and retinoic acid-induced cell membrane receptor and intracellular signal protein changes. RESULTS AND CONCLUSION: SHH specific membrane receptor Ptc, retinoic acid specific receptor RARα, signal protein molecule ptch1 and Smad expressed in normal cells. Ptc expression upregulated in SHH-induced cells. High expression lasted for a long time with induction time, which was significantly stronger compared with the retinoic acid and control groups (P < 0.01). Intracellular ptch1 protein molecule expression showed similar tendency as this, but could not induce upregulation of RARα expression. During induction, retinoic acid-stimulated cells did not activate Ptc pathway. Four days following induction, RARα expression upregulated and lasted till 6 days, but there were no significant differences. No significant change in ptch1 expression was determined. SHH- and retinoic acid-induced cell Smad molecule expression upregulated, but no significant difference was determined. Results verified that SHH-induced scheme participated in cell induction and differentiation by persistently activating its specific receptors. However, there was no significant receptor pathway crossing between retinoic acid-induced and SHH-induced schemes.